For the year ending 2025-12-31, VOR had $312,292K increase in cash & cash equivalents over the period. -$143,654K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Segment expenses | 695,981 |
| Net loss | -695,981 |
| Depreciation expense | 2,887 |
| Non-cash lease expense | 5,647 |
| Stock-based compensation | 18,912 |
| Transaction costs for issuance of pre-funded warrants | 643 |
| Change in fair value of warrant liabilities | 334,358 |
| Interest amortization on marketable securities | 67 |
| Loss (gain) on sale of property and equipment | -3,303 |
| Issuance of pre-funded warrants in connection with the acquisition of in-process research and development | 177,377 |
| Operating lease liabilities | -2,406 |
| Prepaid expenses and other current assets | -1,684 |
| Accounts payable and accrued liabilities | 10,930 |
| Other assets | 0 |
| Net cash used in operating activities | -142,713 |
| Purchases of marketable securities | 53,660 |
| Proceeds from maturities of marketable securities | 5,000 |
| Purchases of property and equipment | 941 |
| Proceeds from sales of property and equipment | 799 |
| Net cash (used in) provided by investing activities | -48,802 |
| Proceeds from the issuance of common stock from private placement | 149,999 |
| Proceeds from the issuance of common stock from underwritten public offering, net of underwriting discount and commissions | 108,101 |
| Proceeds from the issuance of pre-funded warrants | 175,000 |
| Payment of issuance costs related to underwritten public offering and private placements | 1,325 |
| Proceeds from the issuance of common stock from at-the-market sales agreement, net of issuance costs | 70,106 |
| Withholding of shares for tax withholdings upon vesting of restricted stock unit awards | 254 |
| Proceeds from stock option exercises and the issuance of shares under espp | 2,180 |
| Net cash provided by financing activities | 503,807 |
| Net increase in cash, cash equivalents and restricted cash equivalents | 312,292 |
| Cash, cash equivalents and restricted cash equivalents, beginning of period | 84,362 |
| Cash, cash equivalents and restricted cash equivalents, end of period | 396,654 |
Vor Biopharma Inc. (VOR)
Vor Biopharma Inc. (VOR)